Minerva Surgical

Minerva Surgical R&D per Employee

The R&D Spending per Employee of Minerva Surgical (UTRS) as of Nov 3, 2026 is 38,936.31 USD. In the previous year, R&D Spending per Employee was 34,668.79 USD — a change of 12.31% (higher).

R&D per Employee

38,936.31USD

YoY

12.31%

Last updated:

R&D Spending per Employee of Minerva Surgical is 2023 38,936.31 USD. R&D Spending per Employee of Minerva Surgical was 2022 34,668.79 USD. It decreases by 12.31% higher compared to the previous year.

The Minerva Surgical R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
5,955.41 USD
Jan 1, 2020
21,171.97 USD
Jan 1, 2021
33,707.01 USD
Jan 1, 2022
34,668.79 USD
Jan 1, 2023
38,936.31 USD
The Minerva Surgical R&D per Employee history
YEARR&D per EmployeeYoY
38,936.31USD+12.31%
34,668.79USD+2.85%
33,707.01USD+59.21%
21,171.97USD+255.51%
5,955.41USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Minerva Surgical Stock analysis

What does Minerva Surgical do? Minerva Surgical, Inc. generates revenue through the commercialization of minimally invasive uterine healthcare solutions designed to treat abnormal uterine bleeding without necessitating hysterectomies. The company offers a suite of products targeting structural and non-structural causes of AUB, which are utilized by OB/GYNs in hospitals, ambulatory surgical centers, and physician offices. These devices address drawbacks of alternative treatments while preserving the uterus, appealing to healthcare providers seeking effective, non-invasive options for women's health. The firm's product line includes commercially available devices for minimally invasive alternatives to hysterectomy, specifically targeting the most common causes of AUB across various uterine anatomies. OB/GYNs across multiple medical settings purchase these solutions, leveraging their ability to address treatment limitations while avoiding unnecessary surgical interventions. The company's focus on preserving the uterus through non-hysterectomy methods differentiates its offerings in the women's health technology market. Minerva Surgical's revenue model relies on sales of its medical devices to healthcare providers, particularly OB/GYNs, who integrate the products into their treatment protocols for patients with abnormal uterine bleeding. The company's solutions are positioned as alternatives to traditional hysterectomy procedures, targeting a significant unmet need in women's healthcare. This approach allows the firm to capture market share by addressing both clinical and patient preference demands for less invasive care options. Minerva Surgical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Minerva Surgical stock

R&D Spending per Employee of Minerva Surgical is 38,936.31 USD in 2023.

R&D Spending per Employee of Minerva Surgical changed from 34,668.79 USD to 38,936.31 USD, representing a 12.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Minerva Surgical since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Minerva Surgical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Minerva Surgical

All Key Metrics — Minerva Surgical